European Journal of Cancer

Article	Citations
The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers	265
Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies	249
Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts	141
Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment	140
Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)	137
Global, regional and national burden of primary liver cancer by subtype	134
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms	128
Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial	121
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CAC	121
Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts	119
Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients’ perspective	109
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022	107
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis	106
Evidence-based recommendations on categories for extent of resection in diffuse glioma	105
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation	103
The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis	101
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022	99
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR	98
Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer	98
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation	97
Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials	94
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status	91
The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology	90
Evolution of low HER2 expression between early and advanced-stage breast cancer	90
Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and	87

Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study	87
A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19	86
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing	85
Selenium stimulates the antitumour immunity: Insights to future research	84
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy	83
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment	82
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019	82
Exosomes and exosomal RNAs in breast cancer: A status update	81
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel pr	78
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial	75
Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy	75
Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey	73
Gastrointestinal cancer classification and prognostication from histology using deep learning: Systematic review	73
SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death	71
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials	70
Applications of single-cell and bulk RNA sequencing in onco-immunology	65
Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy	65
The current epidemic of HPV-associated oropharyngeal cancer: An 18-year Danish population-based study with 2,169 patients	64
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients	64
Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study	63
Perspectives on natural compounds in chemoprevention and treatment of cancer: an update with new promising compounds	63
Systemic treatment of brain metastases in non-small cell lung cancer	63
High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study	61
Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor–induced secondary adrenal insufficiency	61
Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis	60
Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma	60
Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2)	60
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation	60
Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022	59
Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification	58
Repurposing anticancer drugs for the management of COVID-19	58
Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochem	58
Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease	58
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma	57
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma	54
Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells	53
Immune scores in colorectal cancer: Where are we?	53
How to manage patients with corticosteroids in oncology in the era of immunotherapy?	53
Effect of corticosteroids on the outcome of patients with advanced non–small cell lung cancer treated with immune-checkpoint inhibitors	52
Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial	52
Survival of patients with early-stage cervical cancer after abdominal or laparoscopic radical hysterectomy: a nationwide cohort study and literature review	51
Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications	51
Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943–2036	51
Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial	50
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma	50
SARS-CoV-2 vaccines for cancer patients: a call to action	49
Therapeutic vaccines for breast cancer: Has the time finally come?	49
Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis	49
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib	48
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events	48

STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?	48
A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma	48
Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study	48
Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: A national population-based modelling study in England, UK	47
Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study	47
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer	47
The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey	47
Patients with sarcomatoid renal cell carcinoma – re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors	47
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Pae	46
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?	46
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis	46
Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion	45
The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors	45
European trends in breast cancer mortality, 1980–2017 and predictions to 2025	45
Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study	45
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program	45
Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)	45
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study	44
Explainable artificial intelligence in skin cancer recognition: A systematic review	44
Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy	44
Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review	44
Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis	44
The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region	44
The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience	44
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study	44
Probiotic supplement attenuates chemotherapy-related cognitive impairment in patients with breast cancer: a randomised, double-blind, and placebo-controlled trial	43
Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer	43
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study	43
Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010	43
Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non–small cell lung cancer treated with immunotherapy	43
CRYODESMO-O1: A prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment	42
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice	42
Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study	42
Systematic review and meta-analysis on the impact of lung cancer screening by low-dose computed tomography	42
Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy	41
Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer	41
PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery	41
COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: Seropositivity and safety. A prospective observational study in Italy	41
A prospective multicentre REFCOR study of 470 cases of head and neck Adenoid cystic carcinoma: epidemiology and prognostic factors	41
The impact of ARID1A mutation on molecular characteristics in colorectal cancer	40
Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer	40
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials	40
Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligan	40
Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status	40
A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies	40
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population	39
Hematological immune related adverse events after treatment with immune checkpoint inhibitors	39
European PanCareFollowUp Recommendations for surveillance of late effects of childhood, adolescent, and young adult cancer	39
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organis	39
Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer	39
Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy – a single centre prospective study	39
Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article	39
Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism	39
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis	38
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer	38
Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non–small-cell lung cancer	38
A benchmark for neural network robustness in skin cancer classification	38
Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer – The PICCASSO phase I trial	38
Integration of deep learning-based image analysis and genomic data in cancer pathology: A systematic review	38
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients	38
A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract	37
Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors	37
A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015	37
The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study	37
Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study	37
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022	37
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results	37
Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of th	37
New cancer cases at the time of SARS-Cov2 pandemic and related public health policies: A persistent and concerning decrease long after the end of the national lockdown	37
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study	37
Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy	36
Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours	36
Immune checkpoint inhibitors for cancer and venous thromboembolic events	36
Deep learning can predict lymph node status directly from histology in colorectal cancer	36
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)	36
Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer	36
The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression	36
Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time	36
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies	36
COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study	35

Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial	35
Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial	35
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry	35
Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer	35
Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis	35
Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments	35
Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer	35
Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials	34
Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment	34
Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx	34
Emergency presentations in patients treated with immune checkpoint inhibitors	34
Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy	34
Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study	34
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non–small cell lung cancer	34
Updated EORTC QLQ-C30 general population norm data for Germany	34
Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program	34
D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial	33
Reducing pain and distress related to needle procedures in children with cancer: A clinical practice guideline	33
Immune checkpoint inhibitor–associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation	33
SARS-CoV-2 in children with cancer or after haematopoietic stem cell transplant: An analysis of 131 patients	33
Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care	33
Head and neck mucosal melanoma: The United Kingdom national guidelines	33
Meta-analysis of prospective studies evaluating breast cancer detection and interval cancer rates for digital breast tomosynthesis versus mammography population screening	33
Cancer and coronavirus disease 2019; how do we manage cancer optimally through a public health crisis?	33
Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review	32
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with	32
2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy	32
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial	31
Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)	31
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour	31
Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial	31
Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review	31
Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context	31
Robustness of convolutional neural networks in recognition of pigmented skin lesions	31
Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model	31
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations	30
A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer	30
Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study	30
Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature	30
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial	30
Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it!	30
Sex-differences in symptoms and functioning in >5000 cancer survivors: Results from the PROFILES registry	30
Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial	30
Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer	30
Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials	30
Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations	30
Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical	29
Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients	29
Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools	29
ACCELERATE – Five years accelerating cancer drug development for children and adolescents	29
Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019	29
Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study	29
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis	29
Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer	29
Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies	29
Access and quality of biomarker testing for precision oncology in Europe	29
Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands	29
Bridging the age gap in breast cancer. Impacts of omission of breast cancer surgery in older women with oestrogen receptor positive early breast cancer. A risk stratified analysis of survival outcomes	29
Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis	29
Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer	29
Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy	28
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from	28
Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study	28
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice	28
Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe	28
Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment	28
Current strategies for intratumoural immunotherapy – Beyond immune checkpoint inhibition	28
Development and validation of a pancreatic cancer risk model for the general population using electronic health records: An observational study	28
KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges	28
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis	28
Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS)	28
Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis	28
Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents	27
Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study	27
Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas	27
Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands	27
Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer	27
Ano-uro-genital mucosal melanoma UK national guidelines	27
COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors	27
Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial	27
A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries	27
Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials	27
Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE	27
Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: An analysis of 112 cases	27
Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, O	26
Impact of COVID-19 on healthcare organisation and cancer outcomes	26
Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation	26
Rare use of patient-reported outcomes in childhood cancer clinical trials – a systematic review of clinical trial registries	26
Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial	26
Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer	26
Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer	26
A new prognostic and predictive tool for shared decision making in stage III colon cancer	26
Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma	26
Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments	26
Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: A systematic review and recommendations from the International Late Effects of Childhood Cancer Guide	26